Look at past pharmaceutical companies performance, when their drugs got approved, they went dollars overnight. If one or more $EPGL patents is approved, it could behave similarly to the pharmaceutical approvals because the marker for electronic enhanced contact lenses is just as big as any drug, if not bigger by far.

Who will have shares when patents pending are granted by USPTO? Who will have share when pending licensing deals are announced?